| Literature DB >> 30736479 |
Wen-Ching Huang1, Chen-Chan Wei2, Chi-Chang Huang3, Wen-Lin Chen4, Hui-Yu Huang5,6.
Abstract
A triathlon, which consists of swimming, bicycling, and running, is a high-intensity and long-term form of exercise that can cause injuries such as muscular damage, inflammation, oxidative stress, and energy imbalance. Probiotics are thought to play an important role in disease incidence, health promotion, and nutrient metabolism, but only a few studies have focused on physiological adaptations to exercise in sports science. Previous studies indicated that Lactobacillus supplementation could improve oxidative stress and inflammatory responses. We investigate the effects of Lactobacillus plantarum PS128 supplementation on triathletes for possible physiological adaptation. The triathletes were assigned to one of two groups with different exercise intensity stimulations with different time-points to investigate the effects of body compositions, inflammation, oxidative stress, performance, fatigue, and injury-related biochemical indices. L. plantarum PS128 supplementation, combined with training, can significantly alleviate oxidative stress (such as creatine kinase, Thioredoxin, and Myeloperoxidase indices) after a triathlon (p < 0.05). This effect is possibly regulated by a 6⁻13% decrease of indicated pro-inflammation (TNF-α, IL-6, and IL-8) cytokines (p < 0.05) and 55% increase of anti-inflammation (IL-10) cytokines (p < 0.05) after intensive exercise stimulation. In addition, L. plantarum PS128 can also substantially increase 24⁻69% of plasma-branched amino acids (p < 0.05) and elevate exercise performance, as compared to the placebo group (p < 0.05). In conclusion, L. plantarum PS128 may be a potential ergogenic aid for better training management, physiological adaptations to exercise, and health promotion.Entities:
Keywords: L. plantarum PS128; inflammation; oxidative stress; performance; triathlon
Mesh:
Year: 2019 PMID: 30736479 PMCID: PMC6412901 DOI: 10.3390/nu11020353
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of the triathletes.
| Study I | Study II | |||
|---|---|---|---|---|
| PG | LG | PG | LG | |
| Age (year) | ||||
| Median | 21.1 ± 1.5 | 20.2 ± 0.7 | 20.1 ± 0.3 | 22.3 ± 1.2 |
| Range | 19–24 | 19–21 | 19–21 | 19–26 |
| Height (cm) | 171 ± 5 | 168 ± 8 | 171 ± 1 | 174 ± 1 |
| Weight (kg) | 64.8 ± 5.7 | 63.5 ± 8.5 | 65.6 ± 2.0 | 68 ± 2.8 |
| BMI (kg/m2) | 22.1 ± 1.3 | 22.5 ± 1.2 | 22.4 ± 0.5 | 22.4 ± 0.9 |
| VO2 max (mL/kg/min) | - | - | 60.1 ± 2.2 | 61.8 ± 1.5 |
| Calories (Kcal) | 2002 ± 312 | 2250 ± 143 | 2079 ± 262 | 2048 ± 242 |
The data are represented as mean ± SEM in individual indexes with Study I (n = 18) and II (n = 16). The calories were assessed during the period of probiotics supplementation. PG and LG groups mean the placebo and L. plantarum treatment groups, respectively.
Figure 1Experimental scheme.
Figure 2Body compositions between pre- and post-supplementation in the two studies. The data are represented as mean ± SEM. Study I included subjects (A) pre- and (B) post-supplementation with muscle, fat, and bone percentages (%) in the placebo group (PG) (n = 9) and L. plantarum group (LG) (n = 9). Study II included subjects (C) pre- and (D) post-supplementation with muscle, fat, and bone percentages (%) in the PG (n = 8) and LG (n = 8). p < 0.05 was considered to be a statistically significant difference within and between the groups.
Supplementation effects on fatigue and injury-related biochemical indices (Study I).
| Basal | AfterEx | 3hRest | ||||
|---|---|---|---|---|---|---|
| PG | LG | PG | LG | PG | LG | |
|
| ||||||
| CK (U·L−1) | 171.4 ± 46 | 175.3 ± 40 | 165.4 ± 32 | 155.9 ± 29 | 174.4 ± 34 | 160.5 ± 28 |
| LDH (U·L−1) | 149.4 ± 9 | 138.9 ± 8 | 257.0 ± 30 + | 194.3 ± 15 + | 209.0 ± 14+ | 185.2 ± 15 + |
| Protein carbonyl (nmol·mL−1) | 2.3 ± 0.2 | 2.5 ± 0.2 | 2.5 ± 0.1 | 2.5 ± 0.1 | 2.6 ± 0.1 | 2.6 ± 0.1 |
|
| ||||||
| Ammonia (μmol·L−1) | 153.6 ± 4 | 148.9 ± 5 | 196.6 ± 13 + | 191.2 ± 17 + | 131.6 ± 16 # | 134.6 ± 7.6 # |
| Lactate (mmol·L−1) | 2.6 ± 0.2 | 2.6 ± 0.2 | 7.0 ± 0.9 + | 5.9 ± 1.1 + | 2.1 ± 0.3 # | 2.0 ± 0.3 # |
| FFA (μM) | 134 ± 25 | 113 ± 17 | 360 ± 52 + | 340 ± 53 + | 278 ± 59 + | 250 ± 30 + |
The biochemical indices were collected and assessed from Study I with the sprint triathlon intervention and the sampling time points included Basal, AfterEx, and 3hRest. The data are represented as mean ± SEM. PG (n = 9) and LG (n = 9) indicate the placebo and L. plantarum PS128 supplementation, respectively. + indicates a significant difference compared with the basal point within groups; # indicates a significant difference compared with the AfterEx point within the groups. The significant difference within and between groups was considered when p < 0.016 (0.05/3).
Supplementation effects on fatigue and injury-related biochemical indices (Study II).
| Basal | AfterEx | 3hRest | ||||
|---|---|---|---|---|---|---|
| PG | LG | PG | LG | PG | LG | |
|
| ||||||
| CK (U L−1) | 237.3 ± 45 | 220.1 ± 34 | 662.3 ± 22 + | 548.5 ± 99+ | 1866 ± 67 + | 806.0 ± 13 +, |
| LDH (U L−1) | 242.8 ± 14 | 224.2 ± 8 | 266.3 ± 20 | 258.0 ± 19 | 309.8 ± 22 + | 270.0 ± 19 + |
| Myoglobin (ng mL−1) | 21.8 ± 2 | 21.3 ± 2 | 453.2 ± 144+ | 306.6 ± 47 + | 379.3 ± 134 + | 272.4 ± 30 + |
|
| ||||||
| FFA (μM) | 262 ± 49 | 254 ± 41 | 536 ± 106 + | 462 ± 75 + | 437 ± 59 + | 402 ± 72 + |
The biochemical indices were collected and assessed from Study II with the championship triathlon interventionm and the sampling time points included Basal, AfterEx, and 3hRest. The data are represented as mean ± SEM. PG (n = 9) and LG (n = 9) indicate the placebo and L. plantarum PS128 supplementation, respectively. * indicates a statistically significant difference between the groups; + indicates a significant difference compared with the basal point within the groups; # indicates a significant difference compared with the AfterEx point within the groups. A significant difference within and between groups was considered when p < 0.016 (0.05/3).
Supplementation effects on the cytokine expression profile after exercise (Study I).
| Basal | AfterEx | 3hRest | ||||
|---|---|---|---|---|---|---|
| PG | LG | PG | LG | PG | LG | |
|
| ||||||
| TNF-α (pg/mL) | 11.4 ± 1.3 | 9.9 ± 0.8 | 14.4 ± 1.8 + | 10.5 ± 0.8 * | 15.2 ± 1.9 + | 10.4 ± 0.7 |
| IFN-γ (pg/mL) | 12.3 ± 1.6 | 12.4 ± 2.2 | 12.4 ± 0.9 + | 13.3 ± 2.8 * | 12.1 ± 1.2 + | 12.5 ± 2.1 |
| IL-6 (pg/mL) | 5.8 ± 0.4 | 5.2 ± 0.4 | 9.3 ± 1.2 + | 6.6 ± 0.7 * | 7.6 ± 0.9 + | 5.5 ± 0.5 * |
| IL-8 (pg/mL) | 5.4 ± 0.4 | 5.1 ± 0.4 | 6.9 ± 0.7 + | 5.0 ± 0.4 * | 5.6 ± 0.4 + | 5.4 ± 0.6 |
|
| ||||||
| IL-4 (pg/mL) | 12.0 ± 2.5 | 11.5 ± 2.1 | 13.4 ± 3.3 + | 11.2 ± 2.0 + | 12.3 ± 3.0 + | 11.2 ± 2.0 |
| IL-10 (pg/mL) | 4.4 ± 0.3 | 3.7 ± 0.4 | 8.7 ± 1.1 + | 9.4 ± 1.9 + | 4.1 ± 0.4 # | 3.7 ± 0.3 # |
The cytokine profiles were collected and assessed from Study I with the sprint triathlon intervention, and the sampling time points included Basal, AfterEx, and 3hRest. The data are represented as mean ± SEM. PG (n = 9) and LG (n = 9) indicate the placebo and L. plantarum PS128 supplementation, respectively. * indicates a statistically significant difference between the groups; + indicates a significant difference compared with the basal point within the groups; # indicates a significant difference compared with the AfterEx point within the groups. A significant difference within and between groups was considered when p < 0.016 (0.05/3).
Supplementation effects on the cytokine expression profile after exercise (Study II).
| Basal | AfterEx | 3hRest | ||||
|---|---|---|---|---|---|---|
| PG | LG | PG | LG | PG | LG | |
|
| ||||||
| TNF-α (pg/mL) | 13.9 ± 2.2 | 14.3 ± 1.7 | 22.1 ± 2.4 + | 15.2 ± 1.9 * | 22.5 ± 3.0 + | 15.3 ± 2.2 * |
| IFN-γ (pg/mL) | 2.4 ± 0.4 | 1.7 ± 0.1 | 2.8 ± 0.5 | 1.4 ± 0.1 * | 2.8 ± 0.4 | 1.5 ± 0.1 * |
| IL-6 (pg/mL) | 9.3 ± 1.2 | 7.9 ± 0.5 | 19.7 ± 2.2 + | 14.1 ± 1.3 *,+ | 11.6 ± 1.2 # | 8.0 ± 1.0 *,# |
| IL-8 (pg/mL) | 104.8 ± 12.6 | 98.9 ± 3.2 | 121.3 ± 11 | 92.4 ± 7.4 * | 126.1 ± 11.5 | 98.1 ± 6.8 * |
|
| ||||||
| IL-4 (pg/mL) | 0.8 ± 0.1 | 0.8 ± 0.0 | 0.7 ± 0.0 | 0.7 ± 0.0 | 0.7 ± 0.0 | 0.7 ± 0.0 |
| IL-10 (pg/mL) | 10.5 ± 0.8 | 10.1 ± 0.6 | 84.6 ±1 8 + | 131.7 ± 14 *,+ | 13.3 ± 1.3 +,# | 13.4 ± 1.3 +,# |
The cytokine profiles were collected and assessed from Study II with the championship triathlon intervention, and the sampling time points included Basal, AfterEx, and 3hRest. The data are represented as mean ± SEM. PG (n = 8) and LG (n = 8) indicate the placebo and L. plantarum PS128 supplementation, respectively. * indicates a statistically significant difference between the groups; + indicates a significant difference compared with the basal point within the groups; # indicates a significant difference compared with the AfterEx point within the groups. A significant difference within and between groups was considered when p < 0.016 (0.05/3).
Figure 3The profiles of kidney injury and inflammation-associated markers were collected and assessed from the participants in Study II who engaged in a championship triathlon intervention. (A) TRX (Thioredoxin), (B) C5a (Component 5a), and (C) MPO (Myeloperoxidase) were assessed at multiple time points included Basal, AfterEx, and 3hRest, and the data were represented as mean ± SEM. * indicates a significant difference between groups; + indicates a significant difference compared with the basal point within groups; and # indicates a significant difference compared with the AfterEx point within the groups. The significant difference within and between groups was considered when p < 0.016 (0.05/3).
Supplementation effects on Wingate and VO2 max test after the triathlon championship.
| Pre | Post | |||
|---|---|---|---|---|
| PG | LG | PG | LG | |
|
| ||||
| PP (W) | 843.6 ± 57 | 891.5 ± 42 | 848.8 ± 60 + | 971.6 ± 28 * |
| MP (W) | 631.5 ± 36 | 698.0 ± 28 | 633.0 ± 30 + | 710.4 ± 11 * |
| FI (%) | 50.0 ± 2.2 | 45.2 ± 2.5 | 56.2 ± 1.7 + | 49.8 ± 2.5 * |
|
| ||||
| Endurance (sec) | 1608.3 ± 304 | 2141.5 ± 683 | 898.2 ± 151 + | 1997.5 ± 480 * |
In Study II, the post-Wingate and endurance tests were conducted at 72 and 48 hours, respectively, after the championship triathlon. The data are represented as mean ± SEM, and the PP, MP, and FI correspond to the mean peak power, mean power, and fatigue index, respectively. * indicates a statistically significant difference between the groups, and + indicates a significant difference compared with the basal point within the groups. The significant difference within and between groups was considered when p < 0.05.
Plasma concentrations of free amino acids after the supplementation.
| PG | LG | Normal (nmol/mL) | |
|---|---|---|---|
| Alanine | 465.8 ± 36 | 537.2 ± 69 | 184–590 |
| Arginine | 40.5 ± 4.5 | 39.4 ± 7.3 | 6.45–108 |
| Asparagine | 60.2 ± 2.7 | 65.6 ± 5.2 | 25–74 |
| Aspartic acid | 15.8 ± 2.0 | 13.6 ± 0.4 | 1.0–20 |
| Cysteine | 39.2 ± 2.0 | 44.5 ± 3.2 | 26–90 |
| Glutamic acid | 81.7 ± 3.6 | 87.7 ± 3.3 | 5–120 |
| Glutamine | 618 ± 34 | 653 ± 39 | 350–880 |
| Glycine | 269.0 ± 6 | 275.2 ± 25 | 125–340 |
| Histidine | 91.6 ± 2.6 | 105.6 ± 4.5 * | 56–124 |
| Isoleucine | 63.2 ± 4.9 | 88.7 ± 9.1 * | 37–110 |
| Leucine | 125.5 ± 6.4 | 212.8 ± 60 * | 75–206 |
| Lysine | 167.4 ± 8.0 | 202.2 ± 25 | 93–336 |
| Methionine | 25.2 ± 1.8 | 30.3 ± 3.0 | 5–44 |
| Phenylalanine | 73.8 ± 2.9 | 81.5 ± 7.3 | 36–83 |
| Proline | 247.6 ± 21.4 | 253.7 ± 15.7 | 80–274 |
| Serine | 131.6 ± 5.4 | 140.3 ± 8.9 | 65–183 |
| Threonine | 137.9 ± 7.7 | 165.8 ± 9.4 * | 80–246 |
| Tryptophan | 46.2 ± 6.4 | 39.4 ± 8.1 | 25–73 |
| Tyrosine | 75.6 ± 4.9 | 79.5 ± 3.2 | 43–99 |
| Valine | 257.8 ± 11 | 321.3 ± 20 * | 127–367 |
In Study II, blood amino acid was assessed after three weeks’ supplementation and triathlon championship intervention. The data was represented as mean ± SEM and *, (p < 0.05) means the significant difference between groups. A normal range of amino acid existed in physiological concentrations.